The global bile duct cancer market is anticipated to expand as a result of the rising incidence of bile duct cancer. In Thailand, particularly in the north-east, cholangiocarcinoma is one of the most prevalent cancers, according to statistics from World Cholangiocarcinoma Day in 2016. The highest age-standardized incidence rate is found in Khon Kaen, Thailand, where males are affected at a rate of 84 per 100,000 and females at a rate of 36 per 100,000. Furthermore, 8,000 Americans were diagnosed with bile duct cancer in 2019, according to the American Society of Clinical Oncology (ASCO) report.
The global Bile Duct Cancer Market is estimated to be valued at US$ 185.4 million in 2021 and is expected to exhibit a CAGR of 12.8% over the forecast period (2021-2028).
Prominent Players in the Bile Duct Cancer industry:
1. Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. In November, 2022 Incyte and Mirati Therapeutics, Inc. A clinical-stage targeted oncology company, announced a clinical trial collaboration and supply agreement to investigate the combination of INCB99280, Incyte’s small molecule PD-L1 inhibitor, and adagrasib, a KRASG12C selective inhibitor.
2. Eisai Co., Ltd.
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan. In December, 2022 Yasuda Logistics Corporation and Eisai Co., Ltd. announced that they have entered into a share purchase agreement concerning the transfer of all shares of Eisai’s wholly-owned subsidiary Eisai Distribution Co., Ltd. to Yasuda Logistics.
3. Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. In October. 2022 Agios Pharmaceuticals, Inc. \, a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, and Sagard Healthcare Partners announced that Agios has sold its rights to 5% royalties on U.S. net sales of Servier’s TIBSOVO® (ivosidenib tablets) to Sagard for a one-time payment of $131.8 million.
4. RenovoRx
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
5. Delcath Systems, Inc.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
6. Imbrium Therapeutics L.P.
Founded in 2018, Imbrium is a clinical-stage biopharmaceutical company dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics. The company has headquarters situated in Stamford, CT.
7. Delcath Systems, Inc.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
*Definition- In the case of bile duct cancer, epithelial cells that have undergone mutations display epithelial differentiation. This particular illness is rare.
